After adjusting for potential confounders, the risk for lethal disease among patients with high CYP27A1 tumors remained very significantly elevated in the MDCS cohort for all endpoints and subgroups, especially among older patients ≥ 55 years presenting with ER+ BC, distinctively impairing survival only after 5 years from primary tumor diagnosis. This evidence concerns the gene ESR1 and neoplasm.